abstract |
A therapeutic agent having a specificity for a human CLPTM1L polypeptide, such as a therapeutic agent comprising one or more CLPTM1L-targeting agents, a composition comprising the therapeutic agent, and a cancer, a precancerous lesion or a CLPTM1L protein function disorder (e.g., , ≪ / RTI > variant, or function) associated therewith is provided herein. |